Latest Daily News

Latest News
June 5, 2017

The PD-L1 inhibitor pembrolizumab continued to demonstrate an overall survival benefit compared with chemotherapy among patients with advanced urothelial cancer with no new safety signals.

Read more
June 4, 2017

In patients with upper tract urothelial carcinoma or who have early onset bladder cancer, screening for Lynch syndrome and germline testing is highly recommended.

Read more

June 4, 2017

Adding abiraterone to androgen-deprivation therapy increased overall survival among men with locally advanced or hormone-sensitive metastatic prostate cancer.

Read more
May 25, 2017

Interdisciplinary experts to discuss key issues related to the incorporation of new diagnostic radiopharmaceuticals in the treatment of patients with cancer during ASCO/SNMMI joint session.

Read more
May 25, 2017

Dr. Ulka Vaishampayan discusses the current state of advanced prostate cancer treatment and the need to focus on the optimization of systemic therapies. 

Read more

May 25, 2017

CT imaging is widely available and contains quantitative information, particularly with respect to measuring changes in tumor size. However, there are many differences in how tumor size and response are assessed in clinical trials compared with clinical practice.

Read more
April 7, 2017

The 2017 Genitourinary Cancers Symposium featured a wide variety of novel and important research across a variety of specific fields.

Read more
April 7, 2017

Dr. Neha Vapiwala highlights the findings from the ProtecT trial, which compared surgery, radiation, and active surveillance for the treatment of localized prostate cancer.

Read more

April 7, 2017

Robert Dreicer, MD, MS, FACP, FASCO, answers a question posed by an attendee during a Best of ASCO Meeting.

Read more
June 6, 2016

An education session discussing biomarker identification in prostate cancer, potential future clinical applications for biomarkers, and the steps needed to make potential advances a reality. 

Read more
June 6, 2016

First-line checkpoint inhibitor atezolizumab could be new standard of care for cisplatin-ineligible patients with metastatic urothelial carcinoma. 

Read more

June 7, 2016

In women with platinum-sensitive relapsed ovarian cancer, maintenance therapy with olaparib does not provide a significant overall survival benefit, but long-term therapy is possible, according to an updated analysis of a randomized, double-blind phase II study.

Read more

June 7, 2016

Three abstracts detail data showing the role that evaluation of DNA damage repair genes have in tailoring treatment for metastatic prostate cancer and urothelial carcinoma.

Read more

June 7, 2016

Consideration of clinical trial data and anecdotal patient information can help oncologists weigh available treatment options to either help delay disease progression or avoid hormone therapy for patients with oligometastatic prostate cancer. 

Read more
June 5, 2016

In women with platinum-resistant or platinum-refractory recurrent ovarian cancer, health-related quality of life appears to predict early cessation of chemotherapy and shorter overall survival, and is more sensitive than ECOG performance status, based on an international prospective cohort study.

Read more

May 26, 2016

Drs. Christodouleas, Jason Efstathiou, and Libni Eapen discuss the recent advances in adjuvant radiation for the treatment of locally advanced bladder cancer and NRG Oncology’s NRG-GU001 clinical trial.

Read more

May 26, 2016

Drs. Rana R. McKay and Toni K. Choueiri discuss the ongoing studies exploring novel agents and combinations that will likely inform the future treatment landscape of patients with mRCC.

Read more

May 26, 2016

Dr. Timothy Gilligan discusses the prognosis and preferred treatment of adenocarcinoma of the urinary bladder. 

Read more

May 26, 2016

STAMPEDE uses a multi-arm, multi-stage platform design to answer many questions in a single trial, which saves time and money and makes the trial more efficient and effective than standard trials.

Read more

May 26, 2016

Dr. Rahul Aggarwal discusses the treatment options for patients with neuroendocrine prostate cancer presenting with systemic disease.

Read more